VCYT - Veracyte, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
VCYT price evolution
VCYT
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $237 | $210.27 | $217.33 | |
| Short term investments | ||||
| Net receivables | $48.81 | $50.3 | $46.66 | $40.38 |
| Inventory | $20.36 | $19.26 | $18.33 | $16.13 |
| Total current assets | $356.85 | $321.11 | $290.42 | $285.62 |
| Long term investments | ||||
| Property, plant & equipment | $38.23 | $40.41 | $32.73 | $30.86 |
| Goodwill & intangible assets | $864.64 | $870.2 | $791.58 | |
| Total noncurrent assets | $913.22 | $909.65 | $829.28 | |
| Total investments | ||||
| Total assets | $1275.02 | $1234.33 | $1200.07 | $1114.91 |
| Current liabilities | ||||
| Accounts payable | $9.67 | $12.08 | $12.15 | $12.94 |
| Deferred revenue | $2.19 | $2.6 | $2.01 | |
| Short long term debt | $7.18 | $5.98 | $5.11 | |
| Total current liabilities | $70.31 | $72.34 | $58.05 | $61.24 |
| Long term debt | $0.1 | $0.1 | $8.06 | $7.53 |
| Total noncurrent liabilities | $29.46 | $23.37 | $9.56 | |
| Total debt | $20.74 | $14.04 | $12.63 | |
| Total liabilities | $98.98 | $101.8 | $81.42 | $70.8 |
| Shareholders' equity | ||||
| Retained earnings | -$449.1 | -$464.25 | -$469.99 | -$468.12 |
| Other shareholder equity | -$21.28 | -$30.61 | -$28.91 | -$24.02 |
| Total shareholder equity | $1132.52 | $1118.65 | $1044.1 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $217.33 | $155 | $173.95 | $349.97 |
| Short term investments | $24.61 | |||
| Net receivables | $40.38 | $44.02 | $41.46 | $18.46 |
| Inventory | $16.13 | $14.29 | $11.22 | $4.66 |
| Total current assets | $285.62 | $248.64 | $243.1 | $375.68 |
| Long term investments | ||||
| Property, plant & equipment | $30.86 | $30.86 | $31.14 | $16.83 |
| Goodwill & intangible assets | $791.58 | $870.76 | $910.63 | $62.65 |
| Total noncurrent assets | $829.28 | $907.79 | $944.72 | $81.48 |
| Total investments | $24.61 | |||
| Total assets | $1114.91 | $1156.42 | $1187.83 | $457.16 |
| Current liabilities | ||||
| Accounts payable | $12.94 | $11.91 | $12.36 | $3.12 |
| Deferred revenue | $2.01 | $2.61 | $4.99 | $1.2 |
| Short long term debt | $5.11 | $4.07 | $4.76 | $1.59 |
| Total current liabilities | $61.24 | $62.61 | $64.15 | $16.78 |
| Long term debt | $7.53 | $0.4 | $14.1 | $10.73 |
| Total noncurrent liabilities | $9.56 | $18.61 | $27.16 | $19.15 |
| Total debt | $12.63 | $14.72 | $18.85 | $12.32 |
| Total liabilities | $70.8 | $81.22 | $91.31 | $35.93 |
| Shareholders' equity | ||||
| Retained earnings | -$468.12 | -$393.72 | -$357.16 | -$281.59 |
| Other shareholder equity | -$24.02 | -$31.35 | -$15.08 | |
| Total shareholder equity | $1044.1 | $1075.2 | $1096.51 | $421.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $114.43 | $96.84 | $98.2 | |
| Cost of revenue | $36.52 | $31.46 | $29.38 | |
| Gross Profit | $77.91 | $65.38 | $68.82 | |
| Operating activities | ||||
| Research & development | $16.46 | $15.96 | $18.67 | |
| Selling, general & administrative | $55.96 | $49.99 | $49.05 | |
| Total operating expenses | $73.31 | $70.04 | $104.33 | |
| Operating income | $4.61 | -$4.66 | -$35.51 | |
| Income from continuing operations | ||||
| EBIT | $7.36 | -$1.91 | -$30.47 | |
| Income tax expense | $1.63 | -$0.04 | -$2.18 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $5.73 | -$1.86 | -$28.29 | |
| Income (for common shares) | $5.73 | -$1.86 | -$28.29 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $361.05 | $296.54 | $219.51 | $117.48 |
| Cost of revenue | $112.9 | $101.58 | $74.4 | $41.45 |
| Gross Profit | $248.15 | $194.95 | $145.11 | $76.03 |
| Operating activities | ||||
| Research & development | $57.3 | $40.6 | $29.84 | $17.2 |
| Selling, general & administrative | $187.72 | $174.08 | $181.19 | $89.12 |
| Total operating expenses | $333.94 | $236.03 | $227.02 | $111.42 |
| Operating income | -$85.8 | -$41.08 | -$81.9 | -$35.39 |
| Income from continuing operations | ||||
| EBIT | -$76.61 | -$36.43 | -$81.65 | -$34.68 |
| Income tax expense | -$2.21 | $0.13 | -$6.09 | |
| Interest expense | $0.23 | |||
| Net income | ||||
| Net income | -$74.4 | -$36.56 | -$75.56 | -$34.91 |
| Income (for common shares) | -$74.4 | -$36.56 | -$75.56 | -$34.91 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $5.73 | -$1.86 | -$28.29 | |
| Operating activities | ||||
| Depreciation | $6.89 | $6.73 | $7.36 | |
| Business acquisitions & disposals | $5.01 | |||
| Stock-based compensation | $9.85 | $8.02 | $7.51 | |
| Total cash flows from operations | $29.57 | -$8.97 | $15.55 | |
| Investing activities | ||||
| Capital expenditures | -$2.77 | -$2.13 | -$2.5 | |
| Investments | ||||
| Total cash flows from investing | -$2.13 | -$2.77 | $2.88 | -$2.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.29 | $2.97 | $1.77 | |
| Net borrowings | ||||
| Total cash flows from financing | $9.41 | -$0.01 | -$0.86 | $0.65 |
| Effect of exchange rate | -$0.02 | -$0.06 | -$0.11 | $0.3 |
| Change in cash and equivalents | $57.83 | $26.79 | -$6.95 | $13.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$74.4 | -$36.56 | -$75.56 | -$34.91 |
| Operating activities | ||||
| Depreciation | $31.35 | $29.25 | $21.23 | $8.91 |
| Business acquisitions & disposals | -$736.83 | |||
| Stock-based compensation | $33.14 | $26.73 | $22.52 | $12.99 |
| Total cash flows from operations | $44.22 | $7.54 | -$31.62 | -$9.71 |
| Investing activities | ||||
| Capital expenditures | -$9.96 | -$8.55 | -$5.38 | -$2.84 |
| Investments | $25.07 | -$20.84 | $3 | -$1 |
| Total cash flows from investing | $15.11 | -$29.39 | -$739.21 | -$3.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $9.58 | $7.94 | $605.35 | $207.54 |
| Net borrowings | -$1.28 | -$0.1 | ||
| Total cash flows from financing | $2.84 | $3.49 | $596.32 | $203.59 |
| Effect of exchange rate | $0.16 | -$0.59 | -$1.51 | |
| Change in cash and equivalents | $62.17 | -$18.36 | -$174.51 | $190.05 |
News
|
Tesla, Oaktree among Tuesday's market cap stock movers By Investing.com
Investing.com
25 Feb 2025
|
|
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
Zacks
25 Feb 2025
|
|
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
Zacks · via Yahoo Finance
24 Feb 2025
|
|
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
Zacks · via Yahoo Finance
24 Feb 2025
|
|
High Growth Tech Stocks To Watch In February 2025
Simply Wall St. · via Yahoo Finance
20 Feb 2025
|
|
Is it the Right Time to Hold EYE Stock in Your Portfolio Now?
Zacks · via Yahoo Finance
19 Feb 2025
|
|
Align Technology Shares Hurt by Macro Issues, Decline in ASPs
Zacks · via Yahoo Finance
16 Jan 2025
|
|
HSIC Stock Might Rise Following the Acquisition of Acentus
Zacks · via Yahoo Finance
16 Jan 2025
|
|
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
Zacks · via Yahoo Finance
10 Jan 2025
|
|
MYGN Stock Gains Following Collaboration With Hannah Storm
Zacks · via Yahoo Finance
10 Jan 2025
|
Fundamentals
| Market cap | $2.59B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 77.49M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.07 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.08 |
| Quick ratio | 4.79 |